159 related articles for article (PubMed ID: 24913714)
1. Discovery of a novel series of potent MK2 non-ATP competitive inhibitors using 1,2-substituted azoles as cis-amide isosteres.
Xiao D; Zhu X; Sofolarides M; Degrado S; Shao N; Rao A; Chen X; Aslanian R; Fossetta J; Tian F; Trivedi P; Lundell D; Palani A
Bioorg Med Chem Lett; 2014 Aug; 24(15):3609-13. PubMed ID: 24913714
[TBL] [Abstract][Full Text] [Related]
2. Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors.
Xiao D; Palani A; Huang X; Sofolarides M; Zhou W; Chen X; Aslanian R; Guo Z; Fossetta J; Tian F; Trivedi P; Spacciapoli P; Whitehurst CE; Lundell D
Bioorg Med Chem Lett; 2013 Jun; 23(11):3262-6. PubMed ID: 23602398
[TBL] [Abstract][Full Text] [Related]
3. Structure-based lead identification of ATP-competitive MK2 inhibitors.
Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
[TBL] [Abstract][Full Text] [Related]
4. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.
Powers JP; Li S; Jaen JC; Liu J; Walker NP; Wang Z; Wesche H
Bioorg Med Chem Lett; 2006 Jun; 16(11):2842-5. PubMed ID: 16563752
[TBL] [Abstract][Full Text] [Related]
5. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors.
Rao AU; Xiao D; Huang X; Zhou W; Fossetta J; Lundell D; Tian F; Trivedi P; Aslanian R; Palani A
Bioorg Med Chem Lett; 2012 Jan; 22(2):1068-72. PubMed ID: 22182499
[TBL] [Abstract][Full Text] [Related]
6. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
[TBL] [Abstract][Full Text] [Related]
7. Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors.
Kaptein A; Oubrie A; de Zwart E; Hoogenboom N; de Wit J; van de Kar B; van Hoek M; Vogel G; de Kimpe V; Schultz-Fademrecht C; Borsboom J; van Zeeland M; Versteegh J; Kazemier B; de Roos J; Wijnands F; Dulos J; Jaeger M; Leandro-Garcia P; Barf T
Bioorg Med Chem Lett; 2011 Jun; 21(12):3823-7. PubMed ID: 21565498
[TBL] [Abstract][Full Text] [Related]
8. A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors.
Huang X; Zhu X; Chen X; Zhou W; Xiao D; Degrado S; Aslanian R; Fossetta J; Lundell D; Tian F; Trivedi P; Palani A
Bioorg Med Chem Lett; 2012 Jan; 22(1):65-70. PubMed ID: 22169260
[TBL] [Abstract][Full Text] [Related]
9. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
[TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II.
Revesz L; Schlapbach A; Aichholz R; Dawson J; Feifel R; Hawtin S; Littlewood-Evans A; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4719-23. PubMed ID: 20591669
[TBL] [Abstract][Full Text] [Related]
11. 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2).
Olsson H; Sjö P; Ersoy O; Kristoffersson A; Larsson J; Nordén B
Bioorg Med Chem Lett; 2010 Aug; 20(16):4738-40. PubMed ID: 20643547
[TBL] [Abstract][Full Text] [Related]
12. An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.
Teo T; Yang Y; Yu M; Basnet SK; Gillam T; Hou J; Schmid RM; Kumarasiri M; Diab S; Albrecht H; Sykes MJ; Wang S
Eur J Med Chem; 2015 Oct; 103():539-50. PubMed ID: 26408454
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular-weight MK2 inhibitors: a tough nut to crack!
Schlapbach A; Huppertz C
Future Med Chem; 2009 Oct; 1(7):1243-57. PubMed ID: 21426101
[TBL] [Abstract][Full Text] [Related]
16. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV
Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I.
Revesz L; Schlapbach A; Aichholz R; Feifel R; Hawtin S; Heng R; Hiestand P; Jahnke W; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4715-8. PubMed ID: 20594847
[TBL] [Abstract][Full Text] [Related]
18. Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization.
Crawford TD; Ndubaku CO; Chen H; Boggs JW; Bravo BJ; Delatorre K; Giannetti AM; Gould SE; Harris SF; Magnuson SR; McNamara E; Murray LJ; Nonomiya J; Sambrone A; Schmidt S; Smyczek T; Stanley M; Vitorino P; Wang L; West K; Wu P; Ye W
J Med Chem; 2014 Apr; 57(8):3484-93. PubMed ID: 24673130
[TBL] [Abstract][Full Text] [Related]
19. N-substituted azaindoles as potent inhibitors of Cdc7 kinase.
Bryan MC; Falsey JR; Frohn M; Reichelt A; Yao G; Bartberger MD; Bailis JM; Zalameda L; Miguel TS; Doherty EM; Allen JG
Bioorg Med Chem Lett; 2013 Apr; 23(7):2056-60. PubMed ID: 23481650
[TBL] [Abstract][Full Text] [Related]
20. Theoretical analysis of the binding of potential inhibitors to protein kinases MK2 and MK3.
Araújo PM; da Silva LP; Esteves da Silva JC
Med Chem; 2015; 11(6):573-9. PubMed ID: 25665652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
